David H. Gorski

Dr. David H. Gorski

Wayne State University School of Medicine
+2
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMalathi Banda
Malathi Banda
CSCecilia L. Speyer
Cecilia L. Speyer
SSSara N. Semma
Sara N. Semma
KOKingsley O. Osuala
Kingsley O. Osuala
NKNicole Kounalakis
Nicole Kounalakis
David H. GorskiDavid H. Gorski
David H. Gorski
TNBC is an aggressive breast cancer subtype that does not express hormone receptors (estrogen and progesterone receptors, ER and PR) or amplified human epidermal growth factor receptor type 2 (HER2), and there currently exist no targeted therapies effective against it. Consequently, finding new molecular targets in triple negative breast cancer (TNBC) is critical to improving patient outcomes. Previously, we have detected the expression of metabotropic glutamate receptor-1 (gene: GRM1; protein: mGluR1) in TNBC and observed that targeting glutamatergic signaling inhibits TNBC growth both in vitro and in vivo. In this study, we explored how mGluR1 contributes to TNBC progression, using the isogenic MCF10 progression series, which models breast carcinogenesis from nontransformed epithelium to malignant basal-like breast cancer. We observed that mGluR1 is expressed in human breast cancer and that in MCF10A cells, which model nontransformed mammary epithelium, but not in MCF10AT1 cells, which model atypical ductal hyperplasia, mGluR1 overexpression results in increased proliferation, anchorage-independent growth, and invasiveness. In contrast, mGluR1 knockdown results in a decrease in these activities in malignant MCF10CA1d cells. Similarly, pharmacologic inhibition of glutamatergic signaling in MCF10CA1d cells results in a decrease in proliferation and anchorage-independent growth. Finally, transduction of MCF10AT1 cells, which express c-Ha-ras, using a lentiviral construct expressing GRM1 results in transformation to carcinoma in 90% of resultant xenografts. We conclude that mGluR1 cooperates with other factors in hyperplastic mammary epithelium to contribute to TNBC progression and therefore propose that glutamatergic signaling represents a promising new molecular target for TNBC therapy.

14 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSCecilia L. Speyer
Cecilia L. Speyer
AHAli H. Hachem
Ali H. Hachem
AAAli A. Assi
Ali A. Assi
JJJennifer S. Johnson
Jennifer S. Johnson
JDJohn A. DeVries
John A. DeVries
David H. GorskiDavid H. Gorski
David H. Gorski
Metabotropic glutamate receptors (mGluRs) are normally expressed in the central nervous system, where they mediate neuronal excitability and neurotransmitter release. Certain cancers, including melanoma and gliomas, express various mGluR subtypes that have been implicated as playing a role in disease progression. Recently, we detected metabotropic glutamate receptor-1 (gene: GRM1; protein: mGluR1) in breast cancer and found that it plays a role in the regulation of cell proliferation and tumor growth. In addition to cancer cells, brain endothelial cells express mGluR1. In light of these studies, and because angiogenesis is both a prognostic indicator in cancer correlating with a poorer prognosis and a potential therapeutic target, we explored a potential role for mGluR1 in mediating endothelial cell (EC) proliferation and tumor-induced angiogenesis. GRM1 and mGluR1 were detected in various types of human ECs and, using mGluR1-specific inhibitors or shRNA silencing, we demonstrated that EC growth and Matrigel tube formation are dependent on mGluR1 signaling. In addition, loss of mGluR1 activity leads to reduced angiogenesis in a murine Matrigel sponge implant model as well as a murine tumor model. These results suggest a role for mGluR1 in breast cancer as a pro-angiogenic factor as well as a mediator of tumor progression. They also suggest mGluR1 as a potential new molecular target for the anti-angiogenic therapy of breast cancer.

29 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Neb DuricNeb Duric
Neb Duric
MSMark Sak
Mark Sak
SFShaoqi Fan
Shaoqi Fan
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
PLPeter J Littrup
Peter J Littrup
GGGretchen L. Gierach
Gretchen L. Gierach
Mammographic percent density (MPD) is an independent risk factor for developing breast cancer, but its inclusion in clinical risk models provides only modest improvements in individualized risk prediction, and MPD is not typically assessed in younger women because of ionizing radiation concerns. Previous studies have shown that tissue sound speed, derived from whole breast ultrasound tomography (UST), a non-ionizing modality, is a potential surrogate marker of breast density, but prior to this study, sound speed has not been directly linked to breast cancer risk. To that end, we explored the relation of sound speed and MPD with breast cancer risk in a case-control study, including 61 cases with recent breast cancer diagnoses and a comparison group of 165 women, frequency matched to cases on age, race, and menopausal status, and with a recent negative mammogram and no personal history of breast cancer. Multivariable odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for the relation of quartiles of MPD and sound speed with breast cancer risk adjusted for matching factors. Elevated MPD was associated with increased breast cancer risk, although the trend did not reach statistical significance (OR per quartile = 1.27, 95% CI: 0.95, 1.70; ptrend = 0.10). In contrast, elevated sound speed was significantly associated with breast cancer risk in a dose–response fashion (OR per quartile = 1.83, 95% CI: 1.32, 2.54; ptrend = 0.0003). The OR trend for sound speed was statistically significantly different from that observed for MPD (p = 0.005). These findings suggest that whole breast sound speed may be more strongly associated with breast cancer risk than MPD and offer future opportunities for refining the magnitude and precision of risk associations in larger, population-based studies, including women younger than usual screening ages.

1 September 2014 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
David H. GorskiDavid H. Gorski
David H. Gorski
SNSteven P. Novella
Steven P. Novella

18 September 2014 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
David H. GorskiDavid H. Gorski
David H. Gorski

5 August 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CSCecilia L. Speyer
Cecilia L. Speyer
MBMiriam A. Bukhsh
Miriam A. Bukhsh
WJWaris S. Jafry
Waris S. Jafry
RSRachael E. Sexton
Rachael E. Sexton
SBSudeshna Bandyopadhyay
Sudeshna Bandyopadhyay
David H. GorskiDavid H. Gorski
David H. Gorski